Multiple myeloma is a serious blood cancer, but it is no longer the rapid death sentence it once was. The overall 5-year survival rate is about 62%, and median survival has climbed from roughly 4 years in the early 2000s to over 6 years today, with the newest treatments pushing that number even higher. Still, myeloma remains incurable for most patients. It is a cancer that can damage bones, kidneys, and blood cell production, and nearly all cases eventually relapse after treatment.
What Myeloma Does to the Body
Myeloma starts in plasma cells, a type of white blood cell that normally produces antibodies. When these cells become cancerous, they multiply uncontrollably in the bone marrow and crowd out healthy blood cells. The disease causes damage through four main channels, summarized by doctors with the acronym CRAB: high calcium in the blood, renal (kidney) failure, anemia, and bone disease.
Bone damage is the hallmark problem. Over 80% of myeloma patients develop bone disease, making it the cancer most likely to affect the skeleton. The cancer cells don’t destroy bone directly. Instead, they activate the cells responsible for breaking down bone while simultaneously shutting down the cells that rebuild it. This one-sided process creates characteristic “punched-out” holes visible on X-rays, leading to fractures, bone pain, and spinal compression.
Kidney impairment affects up to 50% of patients at the time of diagnosis, with 2 to 4% needing dialysis right away. The abnormal proteins produced by myeloma cells can clog and damage the tiny filtering structures in the kidneys. Patients with kidney problems at diagnosis have shorter overall survival and a higher risk of early death compared to those whose kidneys are functioning normally.
Anemia develops because the cancerous plasma cells take up space in the bone marrow where red blood cells are produced. High calcium levels occur when bone breaks down faster than the body can clear the released calcium, causing confusion, excessive thirst, constipation, and in severe cases, heart rhythm problems.
Survival Rates and How They’ve Changed
According to the National Cancer Institute’s SEER database (2015 to 2021 data), the 5-year relative survival rate for myeloma that has spread throughout the body, which accounts for 96% of cases at diagnosis, is 61.7%. The small fraction of cases caught while still localized have a 5-year survival of about 81%.
These numbers represent a dramatic improvement over the past two decades. Real-world hospital data shows median survival rising from about 51 months for patients diagnosed between 2000 and 2007, to 72 months for those diagnosed between 2008 and 2015. For patients diagnosed from 2016 onward, median survival hasn’t even been reached yet because too many patients are still alive. The introduction of newer drug classes, including proteasome inhibitors and immunomodulatory drugs, pushed median survival from roughly 57 months with older chemotherapy to 79 and 99 months, respectively. The newest class, anti-CD38 monoclonal antibodies, appears to be pushing survival even further.
Younger patients and those eligible for stem cell transplant have benefited the most from these advances. Globally, myeloma still caused an estimated 121,000 deaths in 2022 out of 188,000 new cases, with about 15,120 deaths in North America alone.
What Makes Some Cases More Aggressive
Not all myeloma behaves the same way. The single biggest predictor of how aggressive the disease will be is the genetic makeup of the cancer cells themselves. Certain chromosomal abnormalities are classified as high-risk because they consistently predict shorter survival, even with modern treatments. The most notorious is a deletion on chromosome 17, found in 5 to 10% of patients at diagnosis, which disables a critical tumor-suppressing gene. Other high-risk changes include specific chromosomal rearrangements found in roughly 15% and 4% of patients, respectively, plus an extra copy of a region on chromosome 1, which appears in 30 to 40% of cases.
Doctors use a staging system called the Revised International Staging System (R-ISS) that combines blood markers with these genetic findings. Stage I patients have low levels of a protein called beta-2 microglobulin, normal albumin, no high-risk genetic changes, and normal enzyme levels. Stage III patients have high beta-2 microglobulin combined with either high-risk genetics or elevated enzyme levels. The difference in outlook between Stage I and Stage III is substantial, making this classification one of the first things your care team will determine.
The Precursor Stage: Smoldering Myeloma
Some people are diagnosed with smoldering myeloma, a precancerous state where abnormal plasma cells are present in the bone marrow but haven’t yet caused organ damage. This stage carries real but variable risk. Across all risk levels, about 23% of smoldering myeloma patients progress to active cancer within two years, and roughly 60% progress within ten years. For those classified as high-risk smoldering myeloma, those numbers jump to 45% at two years and 86% at ten years.
There is a silver lining in the timing. If a patient with smoldering myeloma reaches the five-year mark without progressing, their future risk drops considerably. At that point, only about 14% will progress over the next two years. The median time from a smoldering diagnosis to active myeloma or a related condition is about 4.8 years.
Why Relapse Is the Central Challenge
The core reason myeloma remains serious despite improving survival is that nearly every patient eventually relapses. “Relapsed myeloma” means the cancer has returned after a period of responding to treatment. “Refractory myeloma” means the disease either never responded to a given therapy or came back within 60 days of the last treatment. Some patients are both relapsed and refractory, meaning they initially responded to treatment but their cancer has stopped responding to subsequent attempts.
Each time myeloma returns, it tends to become harder to treat. The cancer cells that survive a round of therapy are, by definition, the ones most resistant to it. When myeloma breaks out of the bone marrow entirely and shows up in soft tissues or the bloodstream (a condition called plasma cell leukemia), median survival drops to around six months or less. This progression from treatable to resistant disease is what makes myeloma a lifelong condition requiring multiple lines of therapy over time.
The Bottom Line on Severity
Myeloma is a serious cancer that causes real organ damage, particularly to bones and kidneys, and cannot be cured in most cases. But “serious” no longer means “quickly fatal.” A patient diagnosed today with standard-risk genetics can reasonably expect to live many years, potentially a decade or more, with a quality of life that would have been unimaginable two decades ago. For those with high-risk genetic features, the outlook is more guarded, but new therapies continue to close that gap. The disease demands ongoing treatment and monitoring, but it has shifted from a cancer measured in months to one increasingly measured in years.